



Diversion Quarterly Q4, 2022

DIVERSION QUARTERLY


As cases of hospital drug diversion continue to make headlines, how does this impact how hospitals are viewed? In [Bluesight's 2022 Patient Perspectives Report](#), 66% of respondents said perceptions of a hospital would be negatively affected if they learned about drug diversion taking place at that hospital and 60% would be driven to seek medical care at alternative hospitals. As always, building trusting relationships between providers and patients continues to be a top priority. Technology solutions, such as ControlCheck, can help identify potential cases of diversion within the hospital, so staff can get the help they need, and patients can receive the exemplary care they deserve.

Bluesight® is sharing data from its ControlCheck platform on a quarterly basis to provide insight into the types of diversions and investigations that may be occurring in hospitals. The following information is as of December 31st, 2022. Data was pulled from health systems across the United States.

Diversion by the Numbers

From October 1st through December 31st, 2022, **18,883,878 controlled substance medications have been tracked** using ControlCheck, bringing the total to **109,141,457 controlled substance medications tracked** since the inception of ControlCheck in September 2018.

Of the **109M+** controlled substance medications tracked, 93.2% of those transactions were automatically closed with no variance, meaning no discrepancies were identified between a medication dispense and the administration of the medication. However, the remaining 6.8% of those transactions were flagged with a potential variance.



Of the 6.8% of controlled substance medication transactions with discrepancies between a medication dispense and the administration of that medication, 48.5% were reviewed and closed without diversion being a contributing factor of the variance. During the timeframe of this report, another 42.7% are still unreviewed and currently open at the hospital. The remaining 8.8% were reviewed, but were unable to be reconciled, meaning there may be cause for an investigation into the transaction to determine if diversion had occurred.



18,883,878 ↑ (19.3%)

controlled substance medications tracked
Oct 1 - Dec 31

109M+ ↑ (20.9%)

total controlled substance medications tracked


298 ↑ (30.1%)
confirmed cases of diversion**

flagged potential diversions an average of

138 Days Sooner

* Increase and decrease metrics are based on quarter over quarter statistics.

**This number shows confirmed cases of diversion, and does not include manually reported cases or suspected diversion.




ControlCheck's IRIS was able to flag potential diversion an average of 138 days sooner than first generation diversion monitoring solutions.

A total of 2,193 hospital workers who were categorized as either an Outlier or Significant Outlier by IRIS left their place of employment before investigations were concluded to determine if diversion was a factor in their ratings.

Timeliness is critical to effectively prevent, detect, and respond to diversion. ControlCheck uses unsupervised machine learning enabling it to continuously learn from ever-changing diversion behavior.

A Closer Look at the Cases

Cases of diversion by role:



Key Takeaways

- Bluesight's ControlCheck has tracked 100M+ medication transactions.
- In Q4 2022, hydromorphone led in variance rate increases, with the variance rate increasing by 5.6%.
- Over the last three years, the percentage of cases automatically closed by ControlCheck has gradually increased, while the percentage of cases flagged with variances has decreased quarter over quarter. This is due to hospitals improving their documentation practices, as well as ControlCheck improving its ability to identify true discrepancies.
- Technology solutions, such as ControlCheck, can flag potential cases of diversion an average of 138 days sooner.

